Cosmos Health Expands Sky Premium Life Into $1Bn+ Kuwait Market; Signs Exclusive Distribution Agreement With Diyar United and Secures Initial Purchase Order of Over 65,000 Units

CHICAGO, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that its subsidiary, SkyPharm S.A., has entered into an exclusive distribution agreement, dated as of September 28, 2025, with Diyar United for the marketing and sale of its Sky Premium Life® line of nutraceuticals in Kuwait.

Diyar United is a respected distributor in Kuwait with extensive healthcare experience. Its strong network, supported by proven logistics and regulatory expertise, makes it a reliable partner to drive Cosmos Health’s expansion into the Kuwaiti market.

Under the agreement, Diyar United will hold the exclusive rights for the registration, promotion, logistics, and distribution of Sky Premium Life® food supplements in Kuwait, spanning formulations such as collagen, hyaluronic acid, vitamins B, C and D3 with K2, magnesium, zinc, turmeric, maca, rhodiola, multivitamins, and hair, skin and nail support blends.

Cosmos Health has secured an initial purchase order of over 65,000 units, reflecting strong demand expectations, with further orders anticipated as the Company builds a growing sales pipeline in Kuwait.

According to Grand View Research, Kuwait’s nutritional supplements market was valued at approximately $1.16 billion in 2024 and is projected to reach $1.68 billion by 2030, growing at a CAGR of around 6.3%. This robust market outlook underscores the significant opportunity for Cosmos Health and its Sky Premium Life® brand as they expand into the country.

Greg Siokas, CEO of Cosmos Health, stated: “This agreement in Kuwait is yet another strong validation of the growing global demand for our Sky Premium Life products. By partnering with Diyar United, a highly respected distributor with proven market expertise, we are confident in our ability to expand successfully in the Middle East. This milestone further reinforces our global growth strategy and advances our mission of establishing Sky Premium Life as a trusted and recognized nutraceutical brand worldwide.”

About Cosmos Health Inc.
Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.

Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans,” and similar expressions, or future or conditional verbs such as “will,” “should,” “would,” “may,” and “could,” generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company’s control, including, but not limited to: the Company’s ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine on the Company’s business, operations, and the economy in general; and the Company’s ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those anticipated. Readers are encouraged to review the risk factors set forth in the Company’s filings with the SEC, which are available at the SEC’s website (www.sec.gov). The Company disclaims any obligation to update or revise forward-looking statements, whether as a result of new information, future events, or otherwise

Investor Relations Contact:
BDG Communications
cosm@bdgcommunications.com

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.